Literature DB >> 32588925

CAR T-Cell Therapy Shows Durable Responses in Indolent NHL.

.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32588925      PMCID： PMC7330923          DOI： 10.1634/theoncologist.2020-0559

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  2 in total

1.  Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Authors:  Frederick L Locke; Armin Ghobadi; Caron A Jacobson; David B Miklos; Lazaros J Lekakis; Olalekan O Oluwole; Yi Lin; Ira Braunschweig; Brian T Hill; John M Timmerman; Abhinav Deol; Patrick M Reagan; Patrick Stiff; Ian W Flinn; Umar Farooq; Andre Goy; Peter A McSweeney; Javier Munoz; Tanya Siddiqi; Julio C Chavez; Alex F Herrera; Nancy L Bartlett; Jeffrey S Wiezorek; Lynn Navale; Allen Xue; Yizhou Jiang; Adrian Bot; John M Rossi; Jenny J Kim; William Y Go; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2018-12-02       Impact factor: 41.316

2.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

Authors:  Carla Casulo; Michelle Byrtek; Keith L Dawson; Xiaolei Zhou; Charles M Farber; Christopher R Flowers; John D Hainsworth; Matthew J Maurer; James R Cerhan; Brian K Link; Andrew D Zelenetz; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2015-06-29       Impact factor: 44.544
  2 in total
  1 in total

1.  Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.

Authors:  Tycel Phillips; Henry Chan; Constantine S Tam; Alessandra Tedeschi; Patrick Johnston; Sung Yong Oh; Stephen Opat; Hyeon-Seok Eom; Heather Allewelt; Jennifer C Stern; Ziwen Tan; William Novotny; Jane Huang; Judith Trotman
Journal:  Blood Adv       Date:  2022-06-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.